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Background: Lipid droplets have been implicated in HCV virion assembly.
Results: Inhibitors of the synthesis of triacylglycerol and cholesterol ester, the main components of lipid droplets, impair virion
assembly.
Conclusion: Production of infectious HCV is linked integrally with the biosynthesis of the major components of lipid droplets.
Significance: Inhibitors of enzymes that generate acylglycerols and cholesterol esters have antiviral activity.
In hepatitis C virus infection, replication of the viral genome
and virion assembly are linked to cellular metabolic processes.
In particular, lipid droplets, which store principally triacylglyc-
erides (TAGs) and cholesterol esters (CEs), have been impli-
cated in production of infectious virus. Here, we examine the
effect on productive infection of triacsin C and YIC-C8-434,
which inhibit synthesis of TAGs and CEs by targeting long-
chain acyl-CoA synthetase and acyl-CoA:cholesterol acyltrans-
ferase, respectively. Our results present high resolution data on
the acylglycerol and cholesterol ester species that were affected
by the compounds.Moreover, triacsinC,whichblocks both trig-
lyceride and cholesterol ester synthesis, clearedmost of the lipid
droplets in cells. By contrast, YIC-C8-434, which only abrogates
production of cholesterol esters, induced an increase in size of
droplets. Although both compounds slightly reduced viral RNA
synthesis, they significantly impaired assembly of infectious
virions in infected cells. In the case of triacsin C, reduced stabil-
ity of the viral core protein, which forms the virion nucleocapsid
and is targeted to the surface of lipid droplets, correlated with
lower virion assembly. In addition, the virus particles that were
released from cells had reduced specific infectivity. YIC-C8-434
did not alter the association of core with lipid droplets but
appeared to decrease production of infectious virus particles,
suggesting a block in virion assembly. Thus, the compounds
have antiviral properties, indicating that targeting synthesis of
lipids stored in lipid dropletsmight be an option for therapeutic
intervention in treating chronic hepatitis C virus infection.
Hepatitis C virus (HCV)3 typically establishes a chronic
infection in the liver that can lead to a range of hepatic disorders
including cirrhosis, hepatocellular carcinoma, and liver failure
(1). Metabolic diseases including insulin resistance and steato-
sis are particular features of chronic infection (2, 3), and there is
now conclusive evidence that factors and pathways involved in
lipidmetabolism are interlinked with various stages of the virus
life cycle (4). First, virus particles are found in association with
lipoprotein in serum, forming lipoviroparticles that are infec-
tious in animal models (5–7). Second, the low density lipopro-
tein receptor and SRB-1, a scavenger receptor for cholesterol,
contribute to virus entry (8, 9). Third, HCV RNA replication is
sensitive to lipid-modulating agents, and finally, virion assem-
bly is thought to be coupled to the assembly pathway for very
low density lipoprotein (VLDL) (10–14). Within this pathway,
storage organelles called lipid droplets (LDs) play a crucial role
in the production of lipoprotein particles (15–17).
Much of the evidence for a role for LDs inHCVvirion assem-
bly has focused on the viral core protein, which is targeted to
the surface of the organelles after maturation by two host
proteases, signal peptidase and signal peptide peptidase (18–
22). The mature form of core can be separated into two
domains: the D1 domain, which has a high proportion of posi-
tively charged residues and binds RNA, and the D2 domain,
which consists of two amphipathic -helices separated by a
hydrophobic loop (23, 24). Mutations in the D2 domain that
disrupt LD attachment reduce the yield of infectious virus (25–
27). Other viral proteins (e.g. NS5A and NS3) are also found in
close proximity to or bound to the surface of LDs in cells pro-
ducing virions (26, 28–30). Moreover, some LDs with attached
viral proteins are juxtaposed to the sites of HCV RNA replica-
tion (25, 26). It has been proposed that such close apposition of
replication sites and LDs coated with viral proteins may indi-
cate sites where the first stages of virion assembly occur.
Because LDs participate in the lipidation of VLDL and infec-
tious virions are associated with lipoprotein, the targeting of
LDs by viral proteins could represent amechanism for the virus
to access the VLDL assembly pathway.
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Although there is evidence for the participation of LDs in
HCV assembly, how they contribute to virion production has
not been fully elucidated. Previously, we have shown that dis-
rupting the redistribution of LDs, which is mediated by the
HCV core protein and requires trafficking by the microtubule
network, reduces virus production (25). Other approaches to
establish the role of LDs in virion assembly have relied on tar-
geting cellular factors that are involved in lipidmetabolism. For
example, a recent report has shown that nordihydroguaiaretic
acid, a hypolipidemic drug that represses fatty acid production
while stimulating fatty acid oxidation (31), suppresses virus
release (32). The mechanism involved in this suppression was
suggested as resulting from an increase in the average size of
LDs that was accompanied by an overall decrease in their num-
ber. The drug also inhibited VLDL secretion apparently by
inducing a decrease in transcription of the microsomal triglyc-
eride transfer protein gene. Comparedwith the broad spectrum
of genes controlling fatty acid metabolism that are affected by
nordihydroguaiaretic acid, specific targeting of diacylglycerol
acyltransferase 1 (DGAT1), which is responsible for the final
step in triglyceride synthesis, impairs virion production (33).
From this study, it has been proposed that virus assembly
requires LDs generated through DGAT1 activity.
The lipid composition of LDs is distinct between the surface
and the core of the organelles. TheLDcore is primarilymade up
of triglycerides (TAGs) and cholesterol esters (CEs), although
diacylglycerides (DAGs) are also incorporated into LDs; the
presence of other lipid species such as free cholesterol and fatty
acids in the LD core cannot be excluded (34–37). Phospholip-
ids predominate at the LD surface,mainly phosphatidylcholine,
but phosphatidylethanolamine, phosphatidylinositol, choles-
terol, lysophosphatidylcholine, and lysophosphatidylethano-
lamine are also detected (34). Interestingly, the phospholipid
monolayer at the surface of LDs has a distinct fatty acid com-
position that differs from that for the endoplasmic reticulum
(38).
Here, we focused on deepening insight into the role of LDs in
HCV infection by modulating the intracellular synthesis of the
two major components of droplets, namely TAGs and CEs,
using two compounds, triacsinC andYIC-C8-434. TriacsinC is
a potent inhibitor of long-chain acyl-CoA synthetase, an en-
zyme that generates fatty acyl-CoAs for incorporation into trig-
lycerides and cholesterol esters (39). Conversely, YIC-C8-434
blocks the conversion of cholesterol to cholesterol esters
through inhibition of Acyl-CoA:cholesterol acyltransferase
(40). Our study examined the impact of these compounds on
the cellular lipidome and distribution of LDs and hence their
effects on HCV RNA replication and virion assembly.
EXPERIMENTAL PROCEDURES
Reagents—YIC-C8-434 and triacsin C were obtained from
Sigma-Aldrich and Enzo Life Sciences, respectively. Chemicals
for lipid extraction (HPLC grade) were purchased from Fisher
Scientific, and lipid standards were supplied by Avanti Polar
Lipids with the exception of TAGs, MAGs, and free fatty acids,
which were obtained from Sigma-Aldrich. The pJFH1 plasmid
and LD540 were gifts fromTakajiWakita (National Institute of
Infectious Diseases, Tokyo, Japan) and Christoph Thiele (Uni-
versity of Bonn), respectively. Antibodies used to detect HCV
core (rabbit antiserum 4210), E2 (AP33; a gift from Arvind
Patel, Glasgow University), dsRNA (J2; supplied by SCICONS,
Hungary), NS5A (sheep antiserum; a gift from Mark Harris,
Leeds University), NS3 (mouse antibody; a gift from Thomas
Pietschmann, TWINCORE, Hannover, Germany), human
apoE (clone EP1374Y; supplied by Abcam), and human Perili-
pin-2 (PLIN2) have been described previously (25, 41–44). For
detection of PLIN2 by indirect immunofluorescence, an anti-
body raised in guinea pig against the protein was used (Progen).
Actin was detected in Western blots with an antibody pur-
chased from Sigma.
Maintenance of Tissue Culture Cells—Huh-7 cells were
propagated in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal calf serum and 100 IU/ml
penicillin-streptomycin.
InVitro Synthesis of RNA, Electroporation of Cells, andTreat-
ment with Compounds—Plasmid pJFH1, which contains the
full-length genomic sequence for HCV strain JFH1 (genotype
2a), was linearized with XbaI and treated with mung bean
nuclease. RNA was transcribed in vitro from linearized DNA
using the T7 RiboMAX Express Large Scale RNA Production
System (Promega). Transcripts were introduced into Huh-7
cells by electroporation as described previously (45). Two days
after electroporationwith JFH1RNA, cells were incubatedwith
the appropriate concentrations of triacsin C and YIC-C8-434
for 5 h followed by a further 24 h with freshmedium containing
the compounds. At the end of treatment, culture medium and
cells were harvested for further analysis.
Concentration of Virus Particles—Virus particles in 30 ml
of culture medium from infected cells were concentrated by
filtration through a 0.45-m filter followed by centrifugation
through a 3-ml cushion of 20% sucrose. Virus particles were
pelleted at 100,000 g for 5 h at 4 °C. Pellets were dissolved in
sample buffer used for SDS-PAGE (see below).
Infection of Cells and Determination of Virus Titers—Super-
natants from cells electroporated with JFH1 RNA were re-
moved at required time points and used to infectmonolayers of
naive Huh-7 cells. Infected cells were detected at 3 days posti-
noculation by indirect immunofluorescence using NS5A anti-
serum. The tissue culture 50% infectious dose (TCID50) was
determined by limiting dilution assay (46). For measuring the
TCID50 of intracellular virus, cells were washed with phos-
phate-buffered saline (PBS), scraped into PBS, and pelleted by
centrifugation at 400  g for 5 min at room temperature. Pel-
leted cells were resuspended in fresh culturemedium, and after
several cycles of freeze-thawing, cell debris was removed by
centrifugation at 1500 g for 5min. The supernatant of the cell
suspension was used to infect Huh-7 cells to determine the
TCID50.
Preparation of Cell Extracts, SDS-PAGE, and Western Blot
Analysis—To prepare extracts, cell monolayers were washed
with PBS and solubilized in sample buffer (160 mM Tris-HCl,
pH 6.7, 2% SDS, 700mM-mercaptoethanol, 10% glycerol, bro-
mophenol blue). Samples were heated at 95 °C for 10 min prior
to electrophoresis through 8, 10, or 12% SDS-polyacrylamide
gels (acrylamide:bisacrylamide ratio of 37.5:1). For Western
blot analysis, proteins were transferred to nitrocellulose
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membrane. After blocking with blocking buffer (PBS con-
taining 5% milk powder (Marvel) and 0.1% Tween 20), mem-
branes were incubated with the relevant primary and HRP-
linked secondary antibodies diluted in blocking buffer. After
washing, bound antibody was detected using ECL Plus (Amer-
sham Biosciences).
Indirect Immunofluorescence Staining and Quantification of
Lipid Droplets—Electroporated cells plated on 13-mm cover-
slips were fixed in methanol at 20 °C for 20 min or in 4%
paraformaldehyde for 1 h at room temperature. After parafor-
maldehyde fixation, cells were permeabilized with 40 g/ml
digitonin for 30min at room temperature. Cells were washed in
PBS and then incubated with primary antibody diluted in PBS/
FCS (PBS containing 1% fetal calf serum) for 2 h at room tem-
perature. Cells were washed extensively with PBS and then
incubated with secondary antibody conjugated to Alexa Fluor
fluorescent tags diluted in PBS/FCS for 60min at room temper-
ature. After washing with PBS, cells were rinsed with distilled
water before mounting on slides using water and sealed with
nail polish. To stain LDs, cells were fixed with 4% paraformal-
dehyde in PBS for a minimum of 1 h followed by washing with
PBS. The cells were then incubated with a 1:2000 dilution of
LD540 (stock solution, 0.5mg/ml in ethanol) in PBS for 30min.
After washing with PBS, cells were rinsed with distilled water
before mounting on slides using water and sealed with nail pol-
ish. Slides were thereafter examined with a Zeiss LSM510
META microscope. Images were recorded with a Plan-Apo-
chromat63 lens (numerical aperture, 1.4). Adobe Photoshop
(CS2) was used for further image processing.
To quantify the numbers of LDs and estimate their sizes,
images of cells stained with LD540 were converted to black and
white pictures, and the same threshold was applied to cell
images usingWCIF ImageJ (open source NIH). Cell areas were
manually drawn, and this region of interest was used to analyze
and calculate average LD size and number in each cell with
ImageJ software.
Buoyant Density Fractionation of HCV Virions—Virions
from the culturemediumwere concentrated by filtration through
a0.45-mfilter followedbycentrifugationat100,000 g for 5h at
4 °C. The pellet was dissolved overnight in PBS at 4 °C and
applied to the top of a continuous 10–40% iodixanol gradient.
After centrifugation at 200,000  g at 4 °C for 16–18 h, frac-
tions were taken from the top and stored at 4 °C for later anal-
ysis of virus titers by measuring secreted embryonic alkaline
phosphatase fromHuh-7/J20 cells as described previously (47).
In short, Huh-7/J20 cells were seeded the day before infection
with the gradient fractions. The cells were incubated for 3 days
at 37 °C after infection with each fraction (in triplicate). Cells
were then lysed with a buffer containing 50 mM Tris-HCl, pH
7.4, 0.1 M NaCl, 1 mM EDTA, and 0.5% Triton X-100. Placental
alkaline phosphatase secretion was measured using the Phos-
pha-Light System from Applied Biosystems according to the
manufacturer’s instructions.
Statistical Analysis—Unpaired t tests were performed in all
cases where statistical validation was required.
Real Time Quantification of RNA—Total cellular and viral
RNAwas extracted fromHuh-7 cells using the RNeasyMini kit
(Qiagen) according to the manufacturer’s instructions. RT-
qPCRs were carried out in two stages. First, cDNA was pro-
duced from total RNA using a TaqMan kit (Applied Biosci-
ences) and random hexamer oligonucleotides following the
manufacturer’s instructions. Reverse transcription was per-
formed in a Thermo Hybaid PX2 thermal cycler using the fol-
lowing conditions: (i) primer annealing at 25 °C for 10 min, (ii)
strand elongation at 37 °C for 1 h, and (iii) reverse transcriptase
inactivation at 95 °C for 5 min. For the second step, cDNAs
were analyzed by qPCR using TaqMan Fast Universal PCR
Master Mix, no AmpErase UNG (Applied Biosystems). Each
sample was run as a singleplex reaction containing appropriate
primers and TaqMan probe or probe/primer mixture. The
HCV probe and primer sequences were located in the 5-UTR
of the JFH1 genome (primers, 5-TCTGCGGAACCGGTGA-
GTAC-3 (nucleotides 147–166) and 5-GCACTCGCAAGC-
ACCCTATC-3 (nucleotides 295–314); probe, 5-GGCCTTG-
TGGTACTG-3 (nucleotides 277–291)). GAPDH probe/
primer mixture (VIC/minor groove binder probe) was purchased
from Applied Biosystems. Reactions were performed using
an Applied Biosystems 7500 Fast Real-Time PCR machine as
follows: (i) dsDNA strand separation at 95 °C for 3 s and (ii)
primer annealing and strand elongation at 60 °C for 30 s. Steps
i and ii were repeated 40 times. All qPCRs were performed in
triplicate, and values were normalized to endogenous GAPDH
levels. Data were analyzed using 7500 Fast System Software
(SDS version 1.3.1, Applied Biosystems).
Lipid Extraction from Cells—Subconfluent Huh-7 cells on
150-mm culture dishes were treated either with DMSO, triac-
sin C, or YIC-C8-434 for a total of 29 h at 37 °C. Growth
medium was then removed, and the cells were washed twice
with PBS. Cells were scraped into 5 ml of PBS and pelleted at
500  g for 10 min. Cell pellets were typically stored for short
periods at20 °C prior to extraction of lipid. To extract lipids,
cell pellets were resuspended in 0.75 ml of ice-cold methanol
and transferred to silanized screw-capped glass tubes. A further
0.75 ml of methanol was used to rinse the container and com-
bined with the initial volume. Internal standards were then
added to allow quantification of lipid species. To this solution,
1.5 ml of 0.9% NaCl and 3 ml of chloroform were added to give
a final proportion of 2:1:1 chloroform:methanol:water (Folch
procedure). This mixture was vortexed vigorously to mix the
organic and aqueous phases and then sonicated in an ice-cooled
ultrasonic bath for 5 min. After a second vortex, the tubes were
centrifuged at 1000  g for 15 min to separate aqueous and
organic phases. The lower organic phase was transferred into a
silanized glass tube using a glass Pasteur pipette. The upper
phase was re-extracted as before with 3 ml of chloroform. Both
lower phases were then combined, and the chloroform was
evaporated. Samples were frozen at20 °C for short term stor-
age before analysis by mass spectrometry.
Mass Spectrometry and Determination of Lipids—A Shi-
madzu ion trap-TOF LC-MS/MS system hyphenated with a
five-channel on-line degasser, four pumps, column oven, and
autosampler with cooler (Prominence HPLC, Shimadzu) was
used for lipid analysis. The lipid classes were separated using a
normal phase silica gel column (2.1  150 mm, 4 m, Micro-
Solv Technology) with hexane/dichloromethane/chloroform/
methanol/acetonitrile/water/ethylamine solvent gradients (48)
HCV Virion Assembly and Lipid Synthesis
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based on the polarity of the headgroup. Accurate mass (mass
accuracy of 5 ppm) and tandem mass spectrometry (MS)
were used for molecular species identification and quantifica-
tion. The identity of lipids was further confirmed by using
appropriate lipid standards. The ion trap-TOF MS operation
conditions were: ESI interface voltage,4.5 kV for positive ESI
and 4 kV for negative ESI; heat block temperature, 230 °C;
nebulizing gas flow, 1.4 liters/min; curved desolvation line tem-
perature, 210 °Cwith drying gas on at a pressure of 100 kilopas-
cals. All the solvents used for lipid extraction and LC-MS/MS
analysis were of LC-MS grade (Fisher Scientific). For choles-
terol (CH) andCE analysis, wemodified themethod of Liebisch
et al. (49). Briefly, lipid extracts remaining from the other lipid
analyses were dried at room temperature using a Thermo
SpeedVac. The dried lipid residues were acetylated with 170ml
of 1:5 (v/v) acetyl chloride:chloroform at room temperature for
2 h. The acetylation solvent was removed at room temperature
under vacuum. The acetylated residues were redissolved in 40
l of 10 mM ammonium acetate in 3:1 (v/v) methanol:chloro-
form, and 7 l was injected via an autosampler for ESI-MS/MS
analysis. A Shimadzu Prominence HPLC hyphenated with
ABSciex 4000QTRAPwas used for CH andCE analysis; 7.5mM
ammonium acetate in 3:1 (v/v) methanol:chloroform (0.25
ml/min) was pumped to the 4000 QTRAP source for ESI-
MS/MS analysis. The followingMS operation parameters were
used: (i) source/gas parameters: curtain gas, 20; collision gas,
medium; ion spray voltage, 5500 V; temperature, 400 °C; ion
source gas 1, 45; ion source gas 2, 20; interface heater, on; (ii)
compound parameters: entrance potential, 9.0; collision cell
exit potential, 11.0; declustering potential, 60 forCE analysis, 50
for acetylated CH analysis; collision energy, 19 for CE analysis,
15 for acetylated CH analysis. Both Q1 and Q3masses were set
at unit resolution for multiple reaction monitoring analysis of
eachmolecular species of CE and CH. For the detailedmultiple
reaction monitoring setup, see Liebisch et al. (49).
RESULTS
Changes in Intracellular Lipid Composition Elicited by Triac-
sin C and YIC-C8-434—In this study, we examined the roles of
LDs and lipid metabolism in HCV infection using compounds
that modulate synthesis of acylglycerides and CEs, the major
components of LDs. Two compounds were selected for this
purpose, triacsin C and YIC-C8-434. Based on cell viability
experiments across a range of concentrations for both com-
pounds, Huh-7 cells had 85% viability after incubation for 29 h
with 0.15 and 0.3 M triacsin C and 10 and 20 M YIC-C8-434
(supplemental Fig. 1); at higher concentrations, cell viability
decreased to less than 80% (data not shown). Therefore, these
subtoxic concentrations were selected for studies on their
effects on intracellular lipids, LDs, and the HCV life cycle.
To determine the alterations in lipid composition following
treatment with the two inhibitors, extracts from cells treated
with triacsin C and YIC-C8-434 were analyzed by HPLC-MS
(Fig. 1). Triacsin C reduced the amount of cellular MAGs,
DAGs, TAGs, and CEs but had no effect on cholesterol levels
(Fig. 1, A and B, panel i in each case). YIC-C8-434 reduced the
level of CEs, andwe observed accompanying rises in cholesterol
as well as MAGs and DAGs, although these did not reach sta-
tistical significance (Fig. 1,A andB, panel i). Examination of the
molecular species of the neutral lipids indicated a selective
effect of triacsin C because not all molecular species were
affected equally. Notably, the amounts of 18:1 MAG and its
likely acylated product 36:2DAG (Fig. 1B, panels ii and iii) were
reduced. The TAG species were generally reduced, although
the minor species TAG 48:1, TAG 50:1, TAG 50:2, and TAG
52:2 appeared to be unaffected as their relative proportions
were significantly elevated (Fig. 1B, panel iv). Fig. 1A (panel ii)
shows no overall change in most CE molecular species follow-
ing triacsin C and YIC-C8-434 treatment except for small but
significant increases in the 16:0 and 18:0 CE species by triacsin
C (both concentrations) and YIC-C8-434 at 10 M. These sub-
tle alterations require more detailed analysis to determine the
apparent selectivity induced by the compounds.
Morphologic Changes to Lipid Droplets following Treatment
with Triacsin C and YIC-C8-434—To further assess the impact
of triacsinC andYIC-C8-434, immunofluorescencewas used to
determine their effect on the abundance, size, and distribution
of LDs. Huh-7 cells were treatedwith both compounds for 29 h,
then fixed, and stained for LDs using LD540, a lipophilic dye
(50). In agreement with previous reports, mock-treated Huh-7
cells contained abundant numbers of LDs that were dispersed
throughout the cell (Fig. 2A, panel i). A similar pattern was
observed for cells treated with DMSO (data not shown). How-
ever, cells incubated with triacsin C were almost completely
devoid of visible LDs (Fig. 2A, panels ii and iii); those that could
be detected tended to cluster toward the cell periphery (Fig. 2A,
panel iii, arrow, and supplemental Fig. 2). In contrast to the
effect of triacsin C, the LDs in cells treated with YIC-C8-434
were larger than those in mock-treated cells (Fig. 2A, panel iv).
To provide a more quantitative assessment of the effects of the
compounds, we also conducted detailed analysis of overall
numbers and sizes of stained LDs in drug-treated cells (Fig. 2, B
and C). The data revealed a significant decrease in the number
of LDs in both triacsin C- and YIC-C8-434-treated cells with
triacsin C-treated cells containing very few LDs (Fig. 2B).
For those cells that retained some LDs after triacsin C treat-
ment, the average size of LDs did not differ significantly from
mock-treated cells (Fig. 2C). However, LDs in YIC-C8-434-
treated cells were on average twice the size of those in mock-
treated cells but could be up to 3 times larger (Fig. 2C). Com-
bined with the overall decrease in the number of stained LDs in
cells treated with YIC-C8-434, the compound may have
induced a modest increase in lipid stored in LDs. This addi-
tional stored lipid could be derived from the greater abundance
of cholesterol, MAGs, and DAGs that is detected in YIC-C8-
434-treated cells. In addition, there may be increased targeting of
cholesterol and acylglycerols fromother cellular compartments to
LDs. From these data, we concluded that triacsin C and YIC-C8-
434 had quite distinct effects on LDs. Blocking synthesis of acyl-
glycerides and CEs with triacsin C significantly decreased the
numbers of LDs, whereas impairing the conversion of CH to CEs
with YIC-C8-434 led to an increase in the size of LDs.
Triacsin C and YIC-C8-434 Impair Virus Production—Previ-
ous reports have shown that compounds that block the early
stages of lipid biosynthesis decrease HCV replication (11, 12,
51, 52). The effect of triacsin C and YIC-C8-434 on viral RNA
HCV Virion Assembly and Lipid Synthesis
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synthesis and virion production was tested using the HCVcc
system, which generates infectious virus that is released from
cells. Huh-7 cells were electroporated with full-length genomic
JFH1 RNA and then treated with either compound at 48 h after
electroporation for a total of 29 h. Relative quantification of
viral RNA in infected cells following drug treatment revealed
that triacsin C reduced HCV transcripts by just over 20% (Fig.
3A). For YIC-C8-434, the drop in viral RNA levels was less
marked (Fig. 3A). In contrast to the modest reduction in viral
RNA levels in cells treated with triacsin C, there was a greater
decrease in virus released from cells that reached 3-fold at the
higher concentration of the drug (Fig. 3A). At this concentra-
tion of triacsin C, the reduction in virus production was signif-
icantly different from any effect of the drug on viral RNA syn-
thesis. YIC-C8-434 lowered the titer of infectious virus to a
similar extent as triacsin C, and there was a significant differ-
ence between the effect on HCV RNA replication and virion
production (Fig. 3A).
Measurement of extracellular virus assesses both intracellu-
lar assembly and subsequent release of virions from infected
cells. To examine whether the reduction in infectious virus
arises from either assembly or release, cells electroporated with
JFH1 RNA and treated with the two drugs were lysed, and the
TCID50 values of intracellular HCVcc were determined. For
both triacsin C andYIC-C8-434, TCID50 values were decreased
by about 5-fold for intracellular virus (Fig. 3B). Hence, although
the compoundsmaypartially impair viral RNAreplication, they
have a more pronounced impact on assembly of infectious
virus.
Antiviral Mechanisms of Action of Triacsin C and YIC-C8-
434—To explore the possiblemechanisms responsible for inhi-
bition of intracellular assembly by triacsin C and YIC-C8-434,
we first examined the impact of the twodrugs on the abundance
of a series of viral proteins as well as PLIN2, a cellular factor
located at the surface of LDs. Two of these viral proteins, core
and NS5A, also are found at the surface of the storage organ-
elles, whereas the other two HCV species examined, E2 and
NS3, are targeted to the endoplasmic reticulum membrane.
JFH1 RNA was electroporated into Huh-7 cells, which were
subsequently treated with triacsin C and YIC-C8-434. After
incubation for 29 h, cell extracts were prepared. Western blot
analysis showed that PLIN2 levels were reduced by more than
70%, particularly at the higher concentration of triacsin C (Fig.
4, A and B), whereas YIC-C8-434 had very little effect on the
abundance of the protein. These results are consistent with the
overall reduction in LDs in triacsin C-treated cells compared
with YIC-C8-434 (Fig. 2B). We found similar patterns for HCV
core and NS5A proteins with levels of core as much as 5-fold
lower following triacsin C treatment (Fig. 4, A and B). By con-
trast, E2 andNS3 were reduced to amuch lesser extent, reflect-
ing the lower HCV RNA synthesis induced by triacsin C, which
would affect the abundance of translated proteins from viral
genomes. These results are consistent with a link between the
presence of intracellular LDs and stability of viral and cellular
FIGURE1.Changes in lipid compositionbroughtaboutby triacsinCandYIC-C8-434. Lipidswere extracted fromcontrol and inhibitor-treated cells, and the
lipid composition was determined by HPLC-ESI-MS. A and B, panel i, the relative total amounts of CEs, CH, MAGs, DAGs, and TAGs in DMSO-, triacsin C- (TC), or
YIC-C8-434 (YIC)-treated cells compared with control cells. A, panel ii, and B, panels ii–iv, the molecular species of each of lipid class was determined and
expressed as apercentageof the total of the specieswithin a lipid class. Error bars represent S.D. of threedeterminations. * representsp0.1, ** isp0.05, and
*** is p 0.01.
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FIGURE 2.Morphologic changes to LDs after treatment with triacsin C and YIC-C8-434. A, Huh-7 cells were mock-treated (panel i) or incubated with 0.15
or 0.3M triacsinC (TC) (panels iiand iii, respectively) or 10MYIC-C8-434 (YIC) (panel iv) for 24h followedby fixationand staining for LDsandnuclei usingLD540
(red) andDAPI (blue), respectively. LDs in theperiphery of the cell are indicatedwith an arrowhead. The scale bar in panel i represents 10m. Thenumber of LDs
(B) and their average size in m (C) per cell was calculated in at least 10 cells for each treatment. Each triangle represents one cell and indicates its respective
number or average size of lipid droplets. The overall average of each condition is shown as a line. *** represents a p value of0.001 in B and0.005 in C.
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factors that bind to them. Thus, the impairment of virus assem-
bly by triacsin C is likely to arise from the reduction in numbers
of LDs and associated lack of stability of core and NS5A pro-
teins. By contrast, YIC-C8-434 did not mediate any reduction
in the viral proteins and therefore presumably decreases virus
assembly by a different mechanism (45, 53).
Having established that YIC-C8-434 did not lower the stabil-
ity of core protein, we examined the effect of the drug on its
intracellular distribution by indirect immunofluorescence. In
parallel, we also analyzed cells treated with triacsin C. Huh-7
cells were electroporated with JFH1 RNA and then treated with
the two drugs as described above. Following drug treatment,
cells were fixed and probed with antibodies against core,
PLIN2, and dsRNA, which has been used previously to identify
putative sites ofHCVRNA replication (25). In cells treated only
with DMSO, core and PLIN2 co-localized, indicating the pres-
ence of core on the surface of LDs (Fig. 4,C,panels i and ii,white
arrows, and D). We also found dsRNA distributed as cytoplas-
mic punctate foci (Fig. 4C, panel iii). In the presence of triacsin
C, PLIN2 was detected in a low proportion of cells, consistent
with the reduction in LDs (Fig. 4C). PLIN2 in such cells tended
to be distributed toward the cell periphery (Fig. 4C, panel v,
white arrow), which would coincide with the remaining LDs
found in triacsin C-treated cells shown in Fig. 2. HCV core
protein was barely detected (Fig. 4C, panel vi) in agreement
with the reduced levels identified byWestern blot analysis (Fig.
4A). By contrast, we found that there was no apparent reduc-
tion in the number of punctate sites recognized by the dsRNA
antibody, indicating the small effect of the drug on HCV RNA
replication (Fig. 4C,panel vii). In cells treatedwithYIC-C8-434,
we did not find any significant reduction in the signals detected
for either PLIN2 or core, and the two proteins co-localized to
the same extent aswithDMSO treatment (Fig. 4C,panels ix and
x, white arrow). This similarity in co-localization between
DMSO- and YIC-C8-434-treated cells was confirmed by deter-
mining Pearson correlation coefficient measurements (Fig.
4D). We conclude therefore that the distribution of core pro-
tein is not altered upon YIC-C8-434 treatment despite the
larger size of the LDs. Moreover, the dsRNA antibody detected
punctate sites, similar to those in DMSO-treated cells, that co-
localize or are in close proximity to core (Fig. 4,C, panels iv and
xii, and D).
Triacsin C but Not YIC-C8-434 Lowers the Specific Infectivity
of Virus Released from Infected Cells—To further examine the
possible impact of triacsin C andYIC-C8-434 on infectivity, the
physical characteristics of extracellular virus following treat-
ment of infected cells with the two drugs were analyzed by
buoyant density centrifugation. HCVcc released from cells
treated with the drugs were layered onto 10–40% iodixanol
density gradients, and gradient fractions were analyzed for
infectivity following centrifugation (Fig. 5A). For comparative
purposes, we included virus released from mock- and DMSO-
treated cells as well as HCVcc produced by a variant that
encoded a glycine to arginine mutation at amino acid residue
451 in the E2 glycoprotein (JFH1/G451R). Previous studies
have shown that the peak of infectivity for this variant has
higher buoyant density as compared with WT HCVcc (54, 55).
For WT HCVcc virions produced in either mock- or DMSO-
treated cells, peak infectivity had a buoyant density of between
1.03 and 1.06 g/ml. By contrast, the buoyant density of JFH1/
G145R virions was higher at between 1.08 and 1.10 g/ml. We
found that the peak of infectious HCVcc made in the presence
of YIC-C8-434 shifted to a higher buoyant density compared
with WT JFH1 (1.05 to 1.08 g/ml), whereas triacsin C did not
shift the density of particles from that forWT virus. This alter-
ation in buoyant density is likely to result from a change in the
lipid content of virus particles released from cells treated with
YIC-C8-434. However, determining the lipid content of virions
purified by both buoyant density centrifugation and affinity
purification has not proven possible (56).
To further examine virus released from infected cells, the
specific infectivity of virions made in the presence of the two
drugs was determined by comparing TCID50 values with the
amount of viral RNA released from cells (Fig. 5B). We found
that for virus released from triacsin C-treated cells TCID50 val-
ues were reduced to a greater extent compared with extracellu-
lar viral RNA; the amount of extracellular RNA released from
triacsin C-treated cells was less than for mock or DMSO treat-
ment, but this reduction correlated with the modest impair-
ment of viral RNA synthesis mediated by triacsin C (see Fig.
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FIGURE 3. Virus production is impaired by triacsin C and YIC-C8-434. Huh-7 cells were electroporated with JFH1 RNA and 48 h later mock-treated or
incubatedwithDMSO, 0.15or 0.3M triacsinC (TC), or 10or 20MYIC-C8-434 (YIC) for 29h. Cellswere lysed andused for RNA isolation andRT-qPCR tomeasure
relative HCV RNA levels in each condition (A, black bars). Culture medium from the last 24 h was used to determine virus titers. These were plotted relative to
mock-treated cells (A,white bars). ** indicates p 0.05 between the relative values of HCV RNA and virus titers calculated from five independent experiments.
In B, cells were subjected to several freeze-thaw cycles to analyze intracellular virus titers from three independent experiments and assessed relative to
mock-treated cells. p 0.1 is indicated by *. Error bars in A and B represent S.D.
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3A). Hence, the specific infectivity of virus released from triac-
sin C-treated cells was reduced compared with either mock- or
DMSO-treated cells. Previous studies have shown that most of
the viral RNA found in the supernatant of infectious cultures
from strain JFH1 is encapsidated in non-infectious particles
that contain core protein (57, 58). From Western blot analysis
of pelletedmaterial from infected cells, the amount of core pro-
tein in extracellular material was slightly lowered by triacsin C
(Fig. 5C), which fits with the reduction in extracellular viral
RNA. We concluded that the lower specific infectivity medi-
ated by triacsin C did not arise from impaired release of viral
RNA but release of particles with lower infectivity. YIC-C8-434
treatment resulted in even less extracellular viral RNA and a
concomitant reduction in core protein (Fig. 5, B and C). This
lowering of viral RNA does not arise from any effect of the drug
on viral RNA synthesis and therefore is presumed to result from
an inhibition of particle assembly and release uponYIC-C8-434
treatment. Combined with the TCID50 values calculated for
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virus released from YIC-C8-434-treated cells, the specific
infectivity of virus was similar to that for mock treatment (Fig.
5A). Hence, YIC-C8-434 treatment appears to block virus pro-
duction, but the released virions have similar infectivity com-
pared with those from mock-treated cells. These effects on
virus generated in the presence of triacsin C and YIC-C8-434
appear unrelated to lipoprotein release as the abundance of
apoE found in supernatants did not change upon treatment of
cells with either drug (Fig. 5C).
DISCUSSION
In this report, we demonstrate that disrupting the pathways
that synthesize the major lipid species of LDs leads to a reduc-
tion in production of infectious HCV. Our approach utilized
two different compounds that had distinct effects on LDs.
Hence, the mechanisms for disrupting virion assembly are
likely to differ between the compounds, illustrating the inti-
mate but somewhat complex link between HCV and LDs.
The lipid analysis shown in Fig. 1 demonstrates clear differ-
ences in the effects of triacsin C and YIC-C8-434 upon cellular
lipids. Although both inhibitors brought about a decrease in
CEs, triacsin C also reduced mono-, di-, and triglycerides. The
reduction in TAGs, DAGs, and CEs by triacsin C is to be
expected as the inhibitor reduces the abundance of acyl-CoA,
which is necessary for their biosynthesis. However, the change
inMAGs ismore difficult to explain directly.MAG is generated
in cells throughTAGandDAGhydrolysis, and thus its decrease
is presumably a reflection not just in synthesis of DAGs and
TAGs but also in their turnover. Examination of the acyl chain
structures of TAGs, DAGs, and MAGs suggests that the addi-
tion of oleoyl groups toMAGs and subsequently TAGs is selec-
tively inhibited by triacsin C. Similarly, it would appear that
oleoyl incorporation into CEs is inhibited by triacsin C,
although this did not reach statistical significance. The lipid
species analysis demonstrated that the reduction in CEs by
YIC-C8-434 is a largely general effect across all species except
for 16:0 and 18:0 CEs, which showed small rises in their relative
proportions.
The different effects upon lipid levels by the two inhibitors
reveal apparent distinct roles for TAGs and CEs in LD struc-
ture. In the triacsin C-treated cells where both TAG and CE
levels were reduced, there was a clear loss of LDs. However, the
reduction in CEs in the YIC-C8-434-treated cells brought
about a reduction in LD number and an increase in their size.
The mechanism underlying this affect on the physical charac-
teristics of LDs is not known but could arise from changing the
balance among CEs, acylglycerols, and CH. We did observe
small increases in MAGs, DAGs, and CH in YIC-C8-434-
treated cells. Such changes in the relative ratios of intracellular
lipids may induce alterations in the physical properties of LDs,
leading to an increase in size. These larger, CE-depleted LDs are
clearly less efficient in promoting viralmaturation. It is possible
that this is due to a distinct alteration in the surface structure of
droplets in addition to a change in their size that leads to
impairment in virus assembly. Alternatively, droplet CEs may
play a key role in virus maturation. The latter hypothesis is
supported by the increased density of virus particles from YIC-
C8-434-treated cells, suggesting that there is an altered associ-
ation between virions and cellular lipids from LDs in such cells.
Another possibility is that the altered size in LDs induced by
YIC-C8-434 may affect the trafficking of LDs, which we previ-
ously demonstrated is linked to virion production (59).
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FIGURE 5. Biophysical characteristics and specific infectivity of virus par-
ticles after treatment with triacsin C and YIC-C8-434. A, 48 h after electro-
porationwith JFH1or JFH1/G451RRNA,Huh-7 cellsweremock-treated (Mock
and G451R) or incubated with DMSO, 0.3 M triacsin C (TC), or 20 M YIC-C8-
434 (YIC) for 29 h. Medium from the last 24 h was collected and subjected to
ultracentrifugation. Pellets containing virus particles were applied to the top
of a continuous 10–40% iodixanol gradient. After centrifugation, 11 fractions
(1–11) were taken from the top; fraction 1 is the top fraction, and fraction 11 is
the bottom fraction. The dashed line indicates the density of the gradient.
Virus titers were determined for all fractions by measuring secreted embry-
onic alkaline phosphatase activity in Huh-7/J20 cells. This figure shows the
percentage of each fraction relative to total infectivity of all fractions for each
individual treatment. B, viral RNA and specific infectivity of virus particles
released from cells treated with triacsin C and YIC-C8-434. Cells were treated
as described inA. Extracellular viral RNA (white bars) was determinedby abso-
lute RT-qPCR, and virus titer was determined by TCID50 analysis (black bars).
Specific infectivity determined from viral RNA and virus titer is shown in gray
bars (n 3). Error bars represent S.D., and * represents p 0.05. C, release of
apoE and HCV core protein from infected cells was determined by Western
blot analysis; virus was concentrated as described under “Experimental Pro-
cedures” prior toWestern blot analysis. Cells were treated with triacsin C and
YIC-C8-434 as described in A. Numbers below the blots indicate the ratio of
core to apoE as determined by densitometry.
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Both inhibitors had small but reproducible suppressive
effects on HCV RNA replication, although inhibition by triac-
sin Cwasmore pronounced than that by YIC-C8-434. Previous
studies have used acetyl-CoA carboxylase, fatty-acid synthase,
and DGAT1 inhibitors to suppress fatty acid biosynthesis and
assess their impact on HCV RNA replication (12, 33, 51, 52).
Both acetyl-CoA carboxylase and fatty-acid synthase function
at the earliest stages of de novo fatty acid production, whereas
DGAT1 acts at the final stage of TAG synthesis. Inhibition of
DGAT1 has no effect on viral RNA replication, whereas block-
ing either acetyl-CoA carboxylase or fatty-acid synthase activ-
ity reduces HCV genome synthesis by at least 50% (12, 33, 51,
52). In the cholesterol pathway, inhibition of the key regulator
HMG-CoA reductase with statins also impairs HCV RNA rep-
lication (11). Collectively therefore, replication requires lipid
species that are synthesized at early stages in TAG and CE
production.
Triacsin C inhibits acyl-CoA synthetase, thereby blocking
production of fatty acyl-CoA, which is an essential substrate for
phospholipid and TAG synthesis as well as esterification of CH
in the CE pathway. Labeling studies have demonstrated that,
although de novo phospholipid synthesis from glycerol is inhib-
ited by triacsin C, there is apparent selective channeling of
available fatty acyl-CoAs toward incorporation into phospho-
lipid (39). Hence, phospholipid levels are less affected by triac-
sinC comparedwith its impact on the abundance of TAGs.Any
slight impairment in phospholipid synthesis by triacsin C could
disrupt the composition of membranes, leading to a reduction
in viral RNA synthesis at the endoplasmic reticulum. Recent
evidence for the importance of acyl-CoA synthetase in the rep-
lication of positive strand RNA viruses has been highlighted
from studies on poliovirus where infection induces increased
acyl-CoA synthetase activity to facilitate the membrane altera-
tions needed for creating sites of RNA replication (60). In con-
trast to triacsin C, YIC-C8-434 blocks only conversion of CH to
CEs through inhibiting acyl-CoA:cholesterol acyltransferase
activity (40). It is possible that any subtle variation in theCH:CE
ratio or the flux of CH through this pathway may disturb the
balance of sterols in the cell and affect membrane fluidity. Such
changes could in turn partially modulate replication complex
formation or viral protein mobility, leading to the modest
decrease in viral RNA levels.
Triacsin C efficiently cleared Huh-7 cells of detectable LDs
and thereby reduced virion assembly by about 3-fold.We found
that the compound also significantly lowered the levels of viral
core and NS5A proteins compared with E2 and NS3. Both core
and NS5A are targeted to the surface of LDs, in particular core,
which is almost exclusively detected on the storage organelles
for strain JFH1 (27). From previous studies, introduction of
mutations into core that disrupt localization to LDs also desta-
bilizes the protein (45, 53). Such a loss in the stability of core
through mutational insertion could result from improper fold-
ing (61) and not necessarily a failure to bind to LDs. In our
studies, decreasing the number of LDs in cells by triacsin C
treatment was sufficient to target core for proteolysis. Hence,
our findings formally demonstrate that core requires LDs as a
platform to maintain protein stability. Such a requirement for
binding to the surface of LDs as amechanism to enable stability
has also been found for other LD-associated proteins such as
PLIN1 and PLIN2, which are degraded upon displacement
from the storage organelles (62–65). In our experiments, deple-
tion of LDs also led to a decrease in PLIN2protein levels. There-
fore, our results are consistent with the general notion that the
stability of LD-associated proteins is intrinsically linked to the
presence of the organelles. Parenthetically, LDs also act as a
junction for regulating protein stability through the ubiquitin-
proteasome pathway. Among the proteins regulated in this
manner is apoB, a major component of VLDL (66, 67). Thus,
LDs not only act as storage organelles for lipids but also as
compartments that regulate the balance between storage and
degradation of proteins (66–69). Presumably, triacsin C-medi-
ated depletion of LDs disrupts these regulatory mechanisms
and perhaps exposes LD-associated proteins to alternative deg-
radative pathways. Ultimately, the consequence of removing
LDs is a decrease in the abundance of core, which would abro-
gate virus particle formation.
Comparedwith triacsin C, YIC-C8-434 did not lead to loss of
LDs but increased their overall size. Nonetheless, treatment of
cells with the compound reduced virion production. We did
not detect any apparent decrease in the abundance of core, and
it retained its distribution on the surface of LDs. Therefore, the
mechanism for impairing virus assembly is likely to be different
from that for triacsin C. Despite the presence of core on LDs,
intracellular infectivity was reduced in YIC-C8-434-treated
cells, indicating a defect in assembly of infectious virus. Target-
ing of core to LDs is mediated by a C-terminal domain, termed
D2. We have found that decreasing the mobility of the D2
domain at the surface of LDs can block virion production.4 We
examined D2 mobility in the presence of YIC-C8-434 but did
not detect any differences compared with untreated cells (data
not shown). Moreover, secretion of apoE, which plays a major
role in VLDL assembly, did not decrease upon YIC-C8-434
treatment (Fig. 5C), suggesting that lipoprotein secretion is
similar in CE-depleted cells compared with normal cells. These
data are in agreement with studies on LDL receptor and acyl-
CoA:cholesterol acyltransferase 2 knock-out mice, which have
a similar amount of VLDL secretion as compared with LDL
receptor-only knock-outmice. Interestingly, the double knock-
outmice secreted VLDLwith depleted levels of CEs but slightly
increased TAGs (70). CE depletion by YIC-C8-434 may alter
the lipid composition of virus particles that are assembled as
part of the cellular VLDLpathway. Indeed, lipidomic analysis of
affinity-purified virus particles suggests that CEs and choles-
terol aremajor lipids in virions (56). Formal demonstration that
the lipid content of infectious virus particles is altered by either
YIC-C8-434 or triacsin C would require isolation of purified
virions from density gradients; however, such an approach has
proven technically challenging because of low yields that are
not feasible for biochemical studies (56).
Although we were unable to examine the composition and
morphology of virions produced in the presence of the two
drugs, we did examine the specific infectivity of the virus parti-
cles released from cells. Virions produced in the presence of
4 A. Filipe, R.Montserret, S. Boulant, F. Penin, and J.McLauchlan,manuscript in
preparation.
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triacsin C had lower specific infectivity, whereas infectivity was
not affected by YIC-C8-434 compared withmock-treated cells.
This suggests that depleting cells of LDs increases the ratio of
non-infectious particles released from cells compared with
those that are infectious. Hence, there may be more than one
route for release of particles containing viral RNA and protein,
but the presence of LDs enhances production of infectious viri-
ons. By contrast, YIC-C8-434 does not affect specific infectivity
but does decrease the overall numbers of viral particles
released. This could be regulated by increased size of LDs and
their disengagement from cell pathways that are necessary for
the entire assembly and release process. We have shown previ-
ously that restricting the mobility of LDs reduces virus assem-
bly (59). It is possible that those LDs, which would typically
participate in virion assembly and release, may be sequestered
in YIC-C8-434-treated cells. Such a situation would not affect
either core localization or stability but could reduce virion
assembly.
Our studies formally demonstrate the importance of LDs to
the assembly pathway for HCV virions. The two compounds
used in the study had quite distinct effects on LDs, but it is
perhaps worth noting that the quantitative changes in total CEs
andTAGswere not dramatic. Therefore, even subtle changes in
the cell lipidome can have significant effects on virus assembly.
The use of acyl-CoA:cholesterol acyltransferase inhibitors in
particular to treat atherosclerosis or hypocholesterolemia has
been explored in the past with little success (71, 72). There is
renewed interest in such compounds because of their potential
as anticancer agents (73). Thus, any agents that target synthesis
of TAGs andCEswith therapeutic value, especially in the devel-
opment of HCV-associated hepatocellular carcinoma, could
display antiviral properties as well as anticancer properties.
This would expand the options for treating chronic HCV infec-
tion, especially in patients with serious liver disease who fre-
quently respond less well to current therapies.
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